PURPOSE: The phosphatidylinositol 3-kinase (PI3K)/PTEN/AKT/mTOR and Ras/Raf/MEK/ERK pathways have been implicated in endometrial tumorigenesis. In this candidate pathway analysis, we investigated associations between genetic variations in these two pathways and both risk and clinical outcomes of endometrial cancer. METHODS: We genotyped a total of 48 potentially functional SNPs in 11 key genes (AKT1, AKT2, AKT3, BRAF, FRAP1, KRAS, PDPK1, PIK3CA, PIK3CB, PIK3R1, and PTEN) with the Sequenom genotyping platform in 115 endometrial cancer patients and 230 cancer-free women to evaluate their associations with risk, survival, and recurrence of endometrial cancer. RESULTS: We found the following: (1) PIK3CA rs6443624 and rs9838411 variants either borderline or significantly decreased risk of endometrial cancer in a dominant model (adjusted odds ratio [OR], 0.62; 95% CI, 0.39-1.00 and 0.59; 95% CI, 0.36-0.95, respectively). Furthermore, there was a statistically significant multiplicative interaction (P (int) = 0.036) between these two loci in risk of endometrial cancer. In contrast, the AKT1 rs2498801 genotype significantly increased risk of endometrial cancer (adjusted OR, 1.94; 95% CI, 1.02-3.67 in a recessive model). (2) In Cox regression analyses, three SNPs (PIK3R1 rs1862162, AKT2 rs892119, and PIK3CA rs2699887) showed significant associations with survival of endometrial cancer patients. (3) KRAS rs7312175 and PIK3CA rs6443624 had significant effects on recurrence of endometrial cancer individually and combined in a locus-dosage manner (adjusted P (trend) = 0.003). CONCLUSION: These results suggest that common genetic variations in these pathways may modulate risk and clinical outcomes of endometrial cancer. Further replication and functional studies are needed to confirm these findings.
PURPOSE: The phosphatidylinositol 3-kinase (PI3K)/PTEN/AKT/mTOR and Ras/Raf/MEK/ERK pathways have been implicated in endometrial tumorigenesis. In this candidate pathway analysis, we investigated associations between genetic variations in these two pathways and both risk and clinical outcomes of endometrial cancer. METHODS: We genotyped a total of 48 potentially functional SNPs in 11 key genes (AKT1, AKT2, AKT3, BRAF, FRAP1, KRAS, PDPK1, PIK3CA, PIK3CB, PIK3R1, and PTEN) with the Sequenom genotyping platform in 115 endometrial cancerpatients and 230 cancer-free women to evaluate their associations with risk, survival, and recurrence of endometrial cancer. RESULTS: We found the following: (1) PIK3CArs6443624 and rs9838411 variants either borderline or significantly decreased risk of endometrial cancer in a dominant model (adjusted odds ratio [OR], 0.62; 95% CI, 0.39-1.00 and 0.59; 95% CI, 0.36-0.95, respectively). Furthermore, there was a statistically significant multiplicative interaction (P (int) = 0.036) between these two loci in risk of endometrial cancer. In contrast, the AKT1rs2498801 genotype significantly increased risk of endometrial cancer (adjusted OR, 1.94; 95% CI, 1.02-3.67 in a recessive model). (2) In Cox regression analyses, three SNPs (PIK3R1rs1862162, AKT2rs892119, and PIK3CArs2699887) showed significant associations with survival of endometrial cancerpatients. (3) KRASrs7312175 and PIK3CArs6443624 had significant effects on recurrence of endometrial cancer individually and combined in a locus-dosage manner (adjusted P (trend) = 0.003). CONCLUSION: These results suggest that common genetic variations in these pathways may modulate risk and clinical outcomes of endometrial cancer. Further replication and functional studies are needed to confirm these findings.
Authors: Katrine Almind; Laurent Delahaye; Torben Hansen; Emmanuel Van Obberghen; Oluf Pedersen; C Ronald Kahn Journal: Proc Natl Acad Sci U S A Date: 2002-02-12 Impact factor: 11.205
Authors: Stephen L Abrams; Linda S Steelman; John G Shelton; Ellis W T Wong; William H Chappell; Jörg Bäsecke; Franca Stivala; Marco Donia; Ferdinando Nicoletti; Massimo Libra; Alberto M Martelli; James A McCubrey Journal: Cell Cycle Date: 2010-05-10 Impact factor: 4.534
Authors: T Minaguchi; H Yoshikawa; K Oda; T Ishino; T Yasugi; T Onda; S Nakagawa; K Matsumoto; K Kawana; Y Taketani Journal: Clin Cancer Res Date: 2001-09 Impact factor: 12.531
Authors: Randi A Paynter; Susan E Hankinson; Graham A Colditz; Peter Kraft; David J Hunter; Immaculata De Vivo Journal: Int J Cancer Date: 2005-08-20 Impact factor: 7.396
Authors: Linda S Steelman; Kristin M Stadelman; William H Chappell; Stefan Horn; Jörg Bäsecke; Melchiorre Cervello; Ferdinando Nicoletti; Massimo Libra; Franca Stivala; Alberto M Martelli; James A McCubrey Journal: Expert Opin Ther Targets Date: 2008-09 Impact factor: 6.902
Authors: Lizelle Correia; Ramiro Magno; Joana M Xavier; Bernardo P de Almeida; Isabel Duarte; Filipa Esteves; Marinella Ghezzo; Matthew Eldridge; Chong Sun; Astrid Bosma; Lorenza Mittempergher; Ana Marreiros; Rene Bernards; Carlos Caldas; Suet-Feung Chin; Ana-Teresa Maia Journal: NPJ Breast Cancer Date: 2022-06-08
Authors: Sadhna R Vora; Dejan Juric; Nayoon Kim; Mari Mino-Kenudson; Tiffany Huynh; Carlotta Costa; Elizabeth L Lockerman; Sarah F Pollack; Manway Liu; Xiaoyan Li; Joseph Lehar; Marion Wiesmann; Markus Wartmann; Yan Chen; Z Alexander Cao; Maria Pinzon-Ortiz; Sunkyu Kim; Robert Schlegel; Alan Huang; Jeffrey A Engelman Journal: Cancer Cell Date: 2014-07-04 Impact factor: 31.743